| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen |
| Ongoing | 4 | 100 | Europe | Somatuline Autogel, Sandostatin LAR, Dostinex, Somavert, Somatuline Autogel, Sandostatin LAR, Dostinex, Somavert | Österreichisches Akromegalie Register, Österreichisches Akromegalieregister | Acromegaly | | | | |
NCT03289741: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide |
|
|
| Completed | 4 | 53 | US | Octreotide, LAR Lanreotide, Questionnaires | Memorial Sloan Kettering Cancer Center | Neuroendocrine Tumors | 04/23 | 04/23 | | |
2013-003998-10: A clinical trial investigating the effect of Lanreotide on reducing fistula output in patients with high output enterocutaneous fistula |
|
|
| Ongoing | 3/4 | 40 | Europe | Lanreotide autosolution, BIM 23014, Solution for injection/infusion, Somatuline AutoSolution 120 mg | Academic medical center, Academic medical center, Ipsen farmaceuticals | All adult patients with a small bowel fistula with an output > 500ml/day or a an enterostomy with an output > 1500ml/day after gastro-intestinal, abdominal wall surgery. Randomization is possible if patients are at least 4 weeks postoperative and had at least 2 weeks of standard care (loperamide, codeine, PPI)., a highoutput pathway between intestine and the skin, either created by a surgeon or spontaneous after complicated surgery, Diseases [C] - Digestive System Diseases [C06] | | | | |
2010-022572-32: Invloed van Somatuline® autogel 120mg op post-operatieve drainage na TME-chirurgie voor rectumcarcinoom |
|
|
| Ongoing | 3 | 50 | Europe | somatuline, Solution for injection, Somatuline 120 mg | Ghent University Hospital, Ipsen NV | Patiënten die een rectumresectie ondergaan voor rectumcarcinoom., Patiënten die een rectumresectie ondergaan voor rectumcarcinoom, Body processes [G] - Biological Phenomena [G16] | | | | |
2022-000507-12: A randomized, controlled, open-label study of RYZ101 compared with standard of care therapy in subjects with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following 177Lu SSA therapy Ensayo aleatorizado, controlado y abierto de RYZ101 frente al tratamiento habitual en sujetos con tumores neuroendocrinos gastroenteropancreáticos bien diferenciados SSTR+, avanzados e inoperables, que hayan progresado tras tratamiento con 177Lu SSA. |
|
|
| Not yet recruiting | 3 | 288 | Europe | RYZ101, Sunitinib, RYZ101, Sunitinib, L01XE04, Solution for injection, Tablet, Capsule, hard, Powder and solvent for suspension for injection, Solution for injection in pre-filled syringe, Everolimus Zentiva 5mg Tabletten, Szunitinib Mylan 12,5 mg, Sandostatin® LAR®- Monatsdepot 30 mg powder and solvent for suspension for injection, SOMATULINE AUTOGEL 120 mg solution for injection in a pre-filled syringe, Szunitinib Sandoz 12,5 mg | RayzeBio, Inc., RayzeBio, Inc. | gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, Diseases [C] - Cancer [C04] | | | | |
NCT06807437: Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula |
|
|
| Not yet recruiting | 3 | 274 | NA | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Distal Pancreatectomy, Lanreotide, Angiopeptin, BIM-23014, DC 13116, Dermopeptin, Ipstyl, Somatulina, Somatuline, Questionnaire Administration, Saline, ISOTONIC SODIUM CHLORIDE SOLUTION, Normal Saline, Sodium Chloride 0.9% | SWOG Cancer Research Network, National Cancer Institute (NCI) | Pancreatic Carcinoma, Pancreatic Neoplasm | 11/27 | 11/27 | | |
| Recruiting | 3 | 288 | Europe, Canada, US, RoW | RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide | RayzeBio, Inc., RayzeBio, Inc. | GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET | 12/25 | 07/28 | | |
| Active, not recruiting | 3 | 332 | Europe, Canada, US, RoW | CAM2029, Octreotide LAR, Lanreotide ATG | Camurus AB, Camurus AB | Gastro-enteropancreatic Neuroendocrine Tumor | 12/25 | 12/27 | | |
2009-012981-30: Prospective study to assess the efficacy and safety of lanreotide 120 mg as treatment of clinical symptoms associated with inoperable intestinal obstruction |
|
|
| Ongoing | 2 | 40 | Europe | Lanreotide, Solution for injection, Somatuline Autogel Injectable | University Hospital Ghent | Inoperable malignant bowel obstruction | | | | |
2011-003687-78: Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) LANREOTIDE AUTOGEL NELTRATTAMENTO DEI PAZIENTI CON FIBROSI POLMONARE IDIOPATICA |
|
|
| Ongoing | 2 | 10 | Europe | Gallium68-Dota-Noc, NA, Solution for injection | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI, IPSEN | Idiopathic Pulmonary Fibrosis Fibrosi polmonare interstiziale idiopatica, Idiopathic Pulmonary Fibrosis Fibrosi polmonare interstiziale idiopatica, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
2013-004232-29: The effect of lanreotide on therapy resistant gastro-esophageal reflux |
|
|
| Ongoing | 2 | 15 | Europe | lanreotide autogel 120 mg, H01CB03, Gel for injection, Somatuline Autogel Injectable 120 mg | UZ Brussel, IPSEN NV | patients with persistent endoscopic reflux in spite of maximal medical therapy with PPI 2 x 40 mg pantoprazole before breakfast and dinner and 300 mg of H2 blocker ranitidine at bedtime AND continuing pathological reflux proven on impedancemetry., Persistent therapy resistant gastric esophageal reflux, Diseases [C] - Digestive System Diseases [C06] | | | | |
2005-004300-36: Use of somatostatin analogue therapy as primary medical treatment of acromegaly |
|
|
| Ongoing | 2 | 10 | Europe | Somatuline Autogel, Somatuline Autogel 60mg, Somatuline Autogel 90mg, Somatuline Autogel 120mg, Somatuline Autogel 60mg, Somatuline Autogel 90mg, Somatuline Autogel 120mg | Plymouth Hospital NHS Trust, R&D dept | Acromegaly | | | | |
2009-016082-29: Role of Lanreotide in the Management of Paraduodenal Pancreatitis |
|
|
| Ongoing | 2 | 60 | Europe | Somatuline Autogel 90 mg, Somatuline Autogel 90 mg | Erasme hospital | Paraduodenal pancreatitis | | | | |
| Ongoing | 2 | 20 | Europe | Metformina TEVA, IPSTYL, [Metformina], [IPSTYL], Tablet, Powder and solvent for solution for injection, METFORMINA TEVA - 30 CPR RIVESTITE IN BLISTER BIANCO OPACO PVC/PVDC/AL DA 850 MG, IPSTYL - 30 MG/2 ML POLVERE E SOLVENTE PER SOSPENSIONE INIETTABILE A RILASCIO PROLUNGATO PER USO INTRAMUSCOLARE1 FLACONE POLVERE + 1 FIALA SOLVENTE 2 ML | FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", IPSEN S.P.A. | Patients with progressive advanced Well-differentiated gastro-intestinal (GI) or lung carcinoids. Tumore neuroendocrino gastro-intestinale (GI) o carcinoide polmonare ben differenziato in stadio avanzato e/o non resecabile, Advanced neuroendocrine tumor Tumore neuroendocrino in stadio avanzato, Diseases [C] - Hormonal diseases [C19] | | | | |
| Active, not recruiting | 2 | 10 | US | Lanreotide, Somatuline Depot | Antonio Fojo, Ipsen | Paraganglioma, Pheochromocytoma | 03/26 | 03/26 | | |
NCT05048901: Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors |
|
|
| Recruiting | 1/2 | 49 | RoW | Cabozantinib, Cabometyx, Lanreotide, Somatuline | National Health Research Institutes, Taiwan, National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Mackay Memorial Hospital, Tri-Service General Hospital, Changhua Christian Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University Chung-Ho Memorial Hospital, Taichung Veterans General Hospital | Neuroendocrine Tumors,Gastroenteropancreatic | 08/26 | 12/26 | | |
ACTRN12620001261909p: A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteers |
|
|
| Not yet recruiting | 1 | 16 | | | Ascil Australia Pty LTD, Ascil Australia Pty LTD | Acromegaly; Neuroendocrine Tumours | | | | |
ACTRN12620001261909: A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteers |
|
|
| Recruiting | 1 | 16 | | | Ascil Australia Pty LTD, Ascil Australia Pty LTD | Acromegaly, Neuroendocrine Tumours | | | | |
| Active, not recruiting | 1 | 20 | Europe | Lanreotide and Metformin, Ipstyl and Metformin | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Neuroendocrine Tumors | 12/21 | 12/21 | | |
OXTEND-01, NCT05364944: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) |
|
|
| Terminated | 1 | 20 | Europe, RoW | Debio 4126, Sandostatin LAR, Octreotide acetate, Somatuline ATG, Lanreotide acetate | Debiopharm International SA | Acromegaly, GEP-NET | 10/24 | 12/24 | | |
| Completed | N/A | 102 | Europe | Lanreotide autogel, Somatostatin Receptor ligand | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Acromegaly | 01/24 | 07/24 | | |
| Completed | N/A | 71 | RoW | Lanreotide autogel | Asan Medical Center, Samsung Medical Center, Seoul St. Mary's Hospital, Severance Hospital, Seoul National University Bundang Hospital | Neuroendocrine Tumors | 01/24 | 01/25 | | |
NCT05431803: Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China |
|
|
| Completed | N/A | 129 | RoW | | Ipsen | Acromegaly | 12/24 | 12/24 | | |
